Generalized Arterial Calcification of Infancy (GACI)

Area of Science:

• Genetics and rare diseases
• Biochemistry and molecular biology
• Pediatric cardiology

Background:

• Generalized arterial calcification of infancy (GACI) is an ultra-rare autosomal recessive disorder.
• Pathogenic variants in ENPP1 and ABCC6 cause loss-of-function, disrupting the PPi/Pi ratio and leading to ectopic mineralization.
• GACI presents with arterial and soft tissue calcification, often resulting in cardiovascular complications and high early mortality.

Purpose of the Study:

• To provide an overview of the current understanding of GACI, including its pathophysiology, clinical manifestations, and management.
• To highlight the shared pathways and features between GACI, pseudoxanthoma elasticum (PXE), and autosomal recessive hypophosphatemic rickets type 2 (ARHR2).
• To discuss current treatment strategies and the need for further research into targeted therapies.

Main Methods:

• Literature review and synthesis of existing research on GACI.
• Analysis of genetic variants (ENPP1, ABCC6) and their impact on pyrophosphate (PPi) metabolism.
• Review of clinical data regarding natural history, symptoms, and treatment outcomes.

Main Results:

• GACI is characterized by ectopic hydroxyapatite mineralization due to PPi/Pi ratio imbalance.
• Long-term natural history reveals complex symptoms including vascular calcifications, soft tissue overmineralization, hypophosphatemia (ARHR2), and skeletal undermineralization.
• Shared pathophysiological pathways exist between GACI, PXE, and ARHR2.

Conclusions:

• Current management of GACI focuses on symptomatic treatment and early intervention with bisphosphonates.
• Multidisciplinary care is essential for managing hypertension, mineral imbalances, hearing loss, and angioid streaks.
• Further research is needed to develop targeted therapies for PPi dysregulation in GACI.